Accueil / Communiqués / Verax Biomedical and Healthtrust® Purchasing Group Enter Agreement for the Use of the Verax Platelet Pgd® Test

Verax Biomedical and Healthtrust® Purchasing Group Enter Agreement for the Use of the Verax Platelet Pgd® Test

Monday, March 4th 2019 at 1:45pm UTC

HealthTrust (HPG), the industry’s only truly committed and aligned
group purchasing model, serves over 1,500 hospitals including five of
the seven largest IDNs in the U.S.

MARLBOROUGH, Mass.–(BUSINESS WIRE)– Enhancing its ability to accelerate growth and meet existing demand, Verax
Biomedical Incorporated
announced today that it has entered into a
three-year laboratory products agreement with HealthTrust
Purchasing Group
(HPG) to support member hospitals with the
implementation of the Verax Platelet PGD Test (PGD).

Every year the U.S.
Food and Drug Administration
(FDA) reports fatal septic events
associated with contaminated platelets that have been tested by early
culture methods. Many hospitals have implemented the PGD Test to address
this risk and participation in this new agreement makes it easier for
HPG hospital members to implement PGD.

“The Platelet PGD test helps protect our patients because it protects
our product. We have peace of mind that we are keeping our patients
safe,” said Charles J. DiComo, Ph.D., Administrative Director, Lab
Services, Integration and Planning at WellSpan
Health
, an HPG member organization. “Since implementing PGD, we now
have a best practice for ensuring patient safety and extending
platelets, which provides better resource management, saves money,
allows us to be a net platelet exporter to surrounding institutions, and
supports us in delivering exceptional patient care in our region.”

The Verax Platelet PGD test not only improves platelet safety but also
offers users the opportunity to move to 7
Day platelet dating
. This enables the typical hospital to save
$250,000 or more annually through reduced platelet outdating according
to data gleaned from Verax’s experience with institutions adopting the
practice.

“In an era of cost constraints impacting hospital operations, the
ability to save money with PGD through extended platelet dating is of
strong appeal to hospitals across the country,” said Verax CEO Jim
Lousararian. “Implementation of PGD offers hospitals the unique
opportunity to address a critical patient risk while saving money at the
same time. We are very excited to help HPG and its members capture these
benefits.”

Every year over 15 percent of apheresis platelets, the costliest blood
component in a hospitals blood inventory, outdate and are discarded. The
average cost to a U.S. hospital of a single apheresis platelet is over
$547 according to a recently published blood utilization survey
published in the journal Transfusion. The average U.S. university
medical center transfuses thousands of apheresis platelets annually.
Extending platelet dating from 5 to 7 days can drastically reduce the
waste of this precious life giving resource.

About Verax Biomedical

Verax is the producer of the Platelet
PGD® Test
, the only rapid test for bacterial contamination in
platelets granted a Safety Measure claim by the FDA. The test can be
used to extend the dating of apheresis platelets in plasma, the most
common platelet type transfused in the U.S., from 5 to 7 days. This
dating extension offers the opportunity for significant cost savings to
the hospital and blood banking community while preserving a critical
life-giving resource. For more information, visit www.veraxbiomedical.com.

About HealthTrust

HealthTrust (legally known as HealthTrust Purchasing Group, L.P. www.healthtrustpg.com)
serves more than 1,500 hospitals and members in 22,600 other locations,
including ambulatory surgery centers, physician practices, long-term
care and alternate care sites. It is headquartered in Brentwood, Tenn.

Contacts

Media Contact:
Joe Sanders
VP Marketing and Business
Development
Verax Biomedical
617-771-8199
jsanders@veraxbiomedical.com

Source: Verax Biomedical


Voir aussi

Poxel Reports Financial Results for Full Year 2018 and Provides Corporate Update

Thursday, March 21st 2019 at 4:45pm UTC Executed strategic agreement for Imeglimin with Roivant Sciences; …